Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey

ÖZET A., DANE F., Aykan N. F., YALÇIN Ş., EVRENSEL T., ÖZKAN M., ...Daha Fazla

FUTURE ONCOLOGY, cilt.18, sa.29, ss.3267-3276, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 29
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2217/fon-2022-0455
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.3267-3276
  • Anahtar Kelimeler: metastatic colorectal cancer, PRECONNECT study, real-world data, trifluridine/tipiracil, Turkish population, NEUTROPENIA, SURVIVAL
  • Erciyes Üniversitesi Adresli: Evet

Özet

Background: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with >= 2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting.